Lates News

Gilead Sciences announced on Tuesday that its once-yearly injectable drug for HIV prevention has received marketing approval from the European Commission. The drug, known as lenacapavir, will be marketed under the brand name Yeytuo in Europe. The drug was approved by US regulators in June for sale in the US under the name Yeztugo. The approval by the European Commission applies to the 27 EU member states, as well as Norway, Iceland, and Liechtenstein. Before providing the drug to patients, Gilead will need to negotiate pricing and reimbursement terms with the healthcare systems of each country. Analysts predict that annual sales of this drug will exceed $4 billion by 2029. The approval by the European Commission allows for the use of this drug as pre-exposure prophylaxis (PrEP) to reduce the risk of HIV infection through sexual transmission for adults and adolescents at high risk of infection with the deadly virus.